Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)

Type 2 diabetes (T2D) remains one of the biggest public health concerns in China, where the disease’s prevalence is globally the highest. Biguanides and alpha-glucosidase inhibitors continue to dominate the market, but the use of SGLT-2 inhibitors and GLP-1 and GIP / GLP-1 receptor agonists in earlier lines of therapy is increasing. The GLP-1 and GIP / GLP-1 receptor agonists combine superior glucose-lowering and weight-loss capabilities in once-weekly and oral formulations, making them very appealing to both patients and physicians. The T2D pipeline mainly comprises drugs from established drug classes, such as DPP-IV inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists, and rapid-acting insulins. We anticipate that the launch of late-phase therapies with more-convenient dosing options will further drive market growth over the 2023-2033 forecast period. In this report, we explore how unmet needs, pricing, coverage, and regulatory reforms in China will impact the success of current and future players in this highly lucrative market.


  • How large is China’s drug-treatable T2D population, and how will drug-treatment rates change during the forecast period?
  • Which are the most commercially relevant drugs in China’s T2D market, and why?
  • What are interviewed experts’ insights into current treatment options?
  • What are the key unmet needs in the management of T2D in China?
  • What are the key market access considerations, and how will they affect the uptake of emerging therapies for T2D in China?
  • What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?


China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

Release Date

April 2024



Primary Research

Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 endocrinologists


Diagnosed prevalence of type 2 diabetes in China, with urban and rural breakup. Clinically and market-relevant drug-treatable populations


10-year, annualized, drug-level sales and patient share of key type 2 diabetes therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions

Emerging Therapies

Phase 3/PR: 10+ drugs; Phase 2: 10+ drugs.

launch Related Market Assessment Reports